Y08284

• Description :

  Y08284 is a potent, selective, oral active CBP bromodomain inhibitor with an IC50 of 4.21 nM. Y08284 suppresses the proliferation of prostate cancer cell lines LNCaP, C4-2B, and 22Rv1. Antitumor activity[1].

• UNSPSC :

  12352005

• Target :

  Epigenetic Reader Domain

• Type :

  Reference compound

• Related Pathways :

  Epigenetics

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/y08284.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C(C1=C2C=C(OC)C=CN2C(C(C)=O)=C1)NC3=CC(C(O)C)=CC(C4=CN(C5CC5)N=C4)=C3F

• Molecular Formula :

  C26H25FN4O4

• Molecular Weight :

  476.50

• References & Citations :

  [1]Xiang Q, et al. Design, Synthesis, and Biological Evaluation of 1- (Indolizin-3-yl) ethan-1-ones as CBP Bromodomain Inhibitors for the Treatment of Prostate Cancer. J Med Chem. 2022;65 (1) :785-810.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [2688745-47-1]